HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 05, May 2017 – Insights Into the Brain & microRNAs       » Omega-3 Therapy May Help Reverse Type 1 Diabetes       » The Potential of Saving Human Lives with Hibernation       » Scientists Unlock TCM Drug's Role in Weight Loss       » Medical Reforms in Beijing       » Fruits and Vegetables' Latest Superpower? Lowering Blood Pressure      
EYE ON CHINA
Chi-Med and Sinopharm form China drug distribution and marketing joint venture

Chi-Med, a pharmaceutical and healthcare company based primarily in China, has established a new joint venture with Sinopharm Group Co. Ltd. (Sinopharm). Sinopharm is the largest distributor of pharmaceutical and healthcare products and a leading value added supply chain service provider in China. The joint venture will provide distribution and marketing services to both related and third party pharmaceutical companies in China.

Chi-Med will, through a wholly-owned subsidiary, invest approximately US$9.8 million in cash into Sinopharm Holding HuYong Pharmaceutical (Shanghai) Co., Ltd. (Huyong) for the subscription of 51% of the equity in the enlarged share capital of Huyong, which will mean that Huyong will be consolidated as a Chi-Med subsidiary. The Chi-Med investment will be largely deployed for expanding future commercial activities, particularly in the area of third party drug sales and marketing.

Huyong is a Good Supply Practice (GSP) certified pharmaceutical and healthcare distribution and marketing company that was originally established in 1993 and subsequently acquired by Sinopharm in 2010. Huyong will be renamed as Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited (Hutchison Sinopharm).

Hutchison Sinopharm will provide a platform for synergy across the China Healthcare Division of Chi-Med by utilizing the services of the approximately 2,800-person prescription drug and over-the-counter drug sales teams of SHPL and HBYS. A major aspect of the Hutchison Sinopharm business strategy will be to provide sales, distribution, and marketing services to major domestic and multi-national third party pharmaceutical manufacturers. It will also provide a broadened sales and marketing platform for HHL's products and potentially the future novel drugs registered by Hutchison MediPharma Limited, Chi-Med's Drug R&D Division.

Click here for the complete issue.

NEWS CRUNCH  
news Healthcare Sustainability in Asia: Now is the Time to Act — FT Asia Healthcare & Life Sciences Summit 2017
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
news 6th Asia-Pacific Breast Cancer Summit to take place in Hong Kong
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Rare Diseases
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy